Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 702 participants.
Also called NCT05920005
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 702 participants
- Registry
-
NCT05920005
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT05920005. Randomized; quadruple masking; primary purpose treatment. Start 2023-08-22 (actual); primary completion 2025-03-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension
- Acronym
- OPTION TREAT
- Condition
- Hypertension
- Intervention (Drug)
- candesartan cilexetil + chlorthalidone + amlodipine
- Intervention (Drug)
- Exforge HCT® (valsartan 160mg + hydrochlorothiazide 12.5mg + amlodipine 5mg)
- Lead sponsor
- Hospital Israelita Albert Einstein
- Collaborator
- Libbs Farmacêutica LTDA
Record details
- Record id
cardio:ct-nct05920005- Content hash
64022ccb21f80e604520dbfcb6ae5e2d3247e66ae4bdd12a3eb6dfe9d0ca253c